Introduction to biomedical polymers and biocompatibility

Biosynthetic Polymers for Medical Applications

Volumn , Issue , 2016, Pages 3-31

  Poole Warren, L A ^a   Patton, A J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biocompatibility; Hybrid biosynthetic polymers; Natural polymers; Synthetic polymers

Indexed keywords

BIOCOMPATIBILITY; HYBRID MATERIALS; NATURAL POLYMERS; TISSUE; TISSUE REGENERATION;

BIOLOGICAL PERFORMANCE; BIOMEDICAL POLYMERS; CONTACTING DEVICES; MEDICAL DEVICES; MEDICAL THERAPY; POLYMER SCIENCE; POLYMER SYNTHESIS; SYNTHETIC POLYMERS;

FUNCTIONAL POLYMERS;

EID: 84960801344     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-78242-105-4.00001-8     Document Type: Chapter

References (64)

1. Gagner J.E., Kim W., Chaikof E.L. Designing protein-based biomaterials for medical applications. Acta Biomater. 2014, 10(4):1542-1557.
2. Whittaker J.W. Cell-free protein synthesis: the state of the art. Biotechnol. Lett. 2013, 35(2):143-152.
3. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010, 123(Pt 24):4195-4200.
4. Schiller J., Huster D. New methods to study the composition and structure of the extracellular matrix in natural and bioengineered tissues. Biomatter 2012, 2(3):115-131.
5. Iozzo R.V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015.
6. Brown B.N., Badylak S.F. Extracellular matrix as an inductive scaffold for functional tissue reconstruction. Transl. Res. 2014, 163(4):268-285.
7. Elastagen Ltd, Elastagen Next generation medical and cosmetic treatments [Online]. Available: (accessed 09.06.15). http://www.elastagen.com/.
8. Ramshaw J.A.M., Peng Y.Y., Glattauer V., Werkmeister J.A. Collagens as biomaterials. J. Mater. Sci. Mater. Med. 2009, 20(Suppl. 1).
9. Jayakrishnan A., Jameela S.R. Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices. Biomaterials 1996, 17(5):471-484.
10. Rubin P.A., Fay A.M., Remulla H.D., Maus M. Ophthalmic plastic applications of acellular dermal allografts. Ophthalmology 1999, 106(11):2091-2097.
11. Moyer H.R., Losken A. The science behind tissue biologics. QMP Plast. Surg. Pulse News 1997, 8-11.
12. Smart N.J., Marshall M., Daniels I.R. Biological meshes: a review of their use in abdominal wall hernia repairs. Surgeon 2012, 10(3):159-171.
13. ™ biologic mesh. Am. Surg. 2013, 79(10):992-996.
14. Sage H., Woodbury R.G., Bornstein P. Structural studies on human type IV collagen. J. Biol. Chem. 1979, 254(19):9893-9900.
15. Advanced Biomatrix Inc., PureCol® - Directions for use [Online]. Available: (accessed 10.06.15). https://www.advancedbiomatrix.com/images/PureCol-Directions-for-Use.pdf.
16. Lynn A.K., Yannas I.V., Bonfield W. Antigenicity and immunogenicity of collagen. J. Biomed. Mater. Res. - Part B Appl. Biomater. 2004, 71(2):343-354.
17. Kim S.K., Kim Y.T., Byun H.G., Nam K.S., Joo D.S., Shahidi F. Isolation and characterization of antioxidative peptides from gelatin hydrolysate of Alaska pollack skin. J. Agric. Food Chem. 2001, 49(4):1984-1989.
18. Zhang Z., Li G., Shi B. Physicochemical properties of collagen, gelatin and collagen hydrolysate derived from bovine limed split wastes. J. Soc. Leather Technol. Chem. 2006, 90(1):23-28.
19. FDA, The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use. Office of the Commissioner [Online]. Available: (accessed 26.05.15). http://www.fda.gov/regulatoryinformation/guidances/ucm125182.htm.
20. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24(24):4337-4351.
21. Mosesson M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 2005, 3(8):1894-1904.
22. Martino M.M., Briquez P.S., Ranga A., Lutolf M.P., Hubbell J.A. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(12):4563-4568.
23. Almine J.F., Wise S.G., Weiss A.S. Elastin signaling in wound repair. Birth Defects Res. Part C - Embryo Today Rev. 2012, 96(3):248-257.
24. Mecham R.P. Methods in elastic tissue biology: elastin isolation and purification. Changes 2012, 29(6):997-1003.
25. Indik Z., Abrams W.R., Kucich U., Gibson C.W., Mecham R.P., Rosenbloom J. Production of recombinant human tropoelastin: characterization and demonstration of immunologic and chemotactic activity. Arch. Biochem. Biophys. 1990, 280(1):80-86.
26. Martin S.L., Vrhovski B., Weiss A.S. Total synthesis and expression in Escherichia coli of a gene encoding human tropoelastin. Gene 1995, 154(2):159-166.
27. You C., Chen H., Myung S., Sathitsuksanoh N., Ma H., Zhang X.-Z., et al. Enzymatic transformation of nonfood biomass to starch. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(18):7182-7187.
28. P. Nguyen, L. Phan, B. Tran, US Patent Application Publication, US Pat. Appl. Publ., vol. 13/353,316, no. 19, 2013.
29. Augst A.D., Kong H.J., Mooney D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 2006, 6(8):623-633.
30. Pawar S.N., Edgar K.J. Alginate derivatization: a review of chemistry, properties and applications. Biomaterials 2012, 33(11):3279-3305.
31. Kuo C.K., Ma P.X. Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: Part 1. Structure, gelation rate and mechanical properties. Biomaterials 2001, 22(6):511-521.
32. Matyash M., Despang F., Ikonomidou C., Gelinsky M. Swelling and mechanical properties of alginate hydrogels with respect to promotion of neural growth. Tissue Eng. Part C Methods 2013, 20(5).
33. Huizhou Foryou Medical Devices Co Ltd., 510(k) Summary: Luofucon Silver Alginate Dressing. FDA 510(k) Summary [Online]. Available: . http://www.accessdata.fda.gov/cdrh_docs/pdf12/K120181.pdf.
34. Marques A.P., Reis R.L., Hunt J.A. The biocompatibility of novel starch-based polymers and composites: In vitro studies. Biomaterials 2002, 23(6):1471-1478.
35. PMA Review, Arista™ AH Absorbable Hemostat. FDA PMA Response Letter [Online] Available:http://www.accessdata.fda.gov/cdrh_docs/pdf5/p050038a.pdf , 2006.
36. Hakim R.M., Fearon D.T., Lazarus J.M. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int. 1984, 26(2):194-200.
37. Kurisawa M., Chung J.E., Yang Y.Y., Gao S.J., Uyama H. Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. Chem. Commun. (Camb) (34) 2005, 4312-4314.
38. Fakhari A., Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater. 2013, 9(7):7081-7092.
39. Center for Devices and Radiological Health, Soft Tissue Fillers (Dermal Fillers) - Soft Tissue Fillers Approved by the Center for Devices and Radiological Health [Online]. Available: (accessed 02.06.15). http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/CosmeticDevices/WrinkleFillers/ucm227749.htm.
40. Coleman S.R. Cross-linked hyaluronic acid fillers. Plast. Reconstr. Surg. 2006, 117(2):661-665.
41. Mojibian H., Spector M., Ni N., Eliseo D., Pollak J., Tal M. Initial clinical experience with a new heparin-coated chronic hemodialysis catheter. Hemodial. Int. 2009, 13(3):329-334.
42. Ye X., Wang H., Zhou J., Li H., Liu J., Wang Z., et al. The effect of heparin-VEGF multilayer on the biocompatibility of decellularized aortic valve with platelet and endothelial progenitor cells. PLoS One 2013, 8(1).
43. Ghanaati S.M., Thimm B.W., Unger R.E., Orth C., Kohler T., Barbeck M., et al. Collagen-embedded hydroxylapatite-beta-tricalcium phosphate-silicon dioxide bone substitute granules assist rapid vascularization and promote cell growth. Biomed. Mater. 2010, 5(2):25004.
44. Wang X., Bank R.A., TeKoppele J.M., Mauli Agrawal C. The role of collagen in determining bone mechanical properties. J. Orthop. Res. 2001, 19(6):1021-1026.
45. Burton B., Gaspar A., Josey D., Tupy J., Grynpas M.D., Willett T.L. Bone embrittlement and collagen modifications due to high-dose gamma-irradiation sterilization. Bone 2014, 61:71-81.
46. ISO 10993-1:2009 Biological evaluation of medical devices Part 1: Evaluation and testing in the risk management process.
47. FDA, Good Laboratory Practice Regulations (21 CFR Part 58). Code of Federal Regulations [Online]. Available: . http://www.fda.gov/ohrms/dockets/98fr/980335s1.PDF.
48. Williams D.F. The Williams Dictionary of Biomaterials 1999, vol. 5. Liverpool University Press.
49. FDA Centre for Devices and Radiological Health, Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing, Draft Guidance Document (issued 23.04.13).
50. Schoen F.J., Levy R.J. Tissue heart valves: current challenges and future research perspectives. J. Biomed. Mater. Res. 1999, 47(4):439-465.
51. Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann. Thorac. Surg. 2005, 79(3):1072-1080.
52. Rieder E., Kasimir M.T., Silberhumer G., Seebacher G., Wolner E., Simon P., et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J. Thorac. Cardiovasc. Surg. 2004, 127(2):399-405.
53. Bell E., Ivarsson B., Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. Acad. Sci. U.S.A. 1979, 76(3):1274-1278.
54. Brown R.A. In the beginning there were soft collagen-cell gels: towards better 3D connective tissue models. Exp. Cell Res. 2013, 319(16):2460-2469.
55. Wong M.L., Griffiths L.G. Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization. Acta Biomater. 2014, 10(5):1806-1816.
56. Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2002, 2(5):346-353.
57. ISO 10993-10:2010 Biological evaluation of medical devices Part 10: Tests for irritation and delayed-type hypersensitivity.
58. ISO 10993-20:2006 Biological evaluation of medical devices Part 20: Principles and methods for immunotoxicology testing of medical devices.
59. Lucey P., Goldberg D.J. Complications of collagen fillers. Facial Plast. Surg. December 2014, 30(6):615-622.
60. Milland J., Sandrin M.S. ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens 2006, 68(6):459-466.
61. Geng J., Mantovani G., Tao L., Nicolas J., Chen G., Wallis R., et al. Site-directed conjugation of 'clicked' glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function. J. Am. Chem. Soc. 2007, 129(49):15156-15163.
62. Watts J.C., Prusiner S.B. Mouse models for studying the formation and propagation of prions. J. Biol. Chem. 2014, 289(29):19841-19849.
63. Fraser P.E. Prions and prion-like proteins. J. Biol. Chem. 2014, 289(29):19839-19840.
64. FDA, "Medical Devices Containing Materials Derived from Animal Sources," FDA guidance documents [Online]. Available: http://www.fda.gov/downloads/Medical Devices/DeviceRegulationandGuidance/GuidanceDocuments/UCM381491.pdf, 2014 (accessed 02.06.15).